Clinical trials: PET Imaging in Patients With Prostate Cancer, active
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Prostate Cancer, PI-RADS 3 Prostate Lesion
POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions
This prospective, multicenter diagnostic accuracy study will evaluate whether POSLUMA (flotufolastat F 18) PET/MRI or PET/CT can detect clinically significant prostate cancer, defined as Gleason score 7 or higher, in adult men…
- Trial name
- PRISM (NCT07916311)
- Testing
- PET Imaging with Flotufolastat F 18
- Where
- 6 sites in United States
- Volunteers
- 130 people
- Sponsor
- SimonMed Imaging
Prostate Cancer
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade).
- Trial name
- uTRACE-101 (NCT06474806)
- Testing
- 64Cu-DOTA-AE105
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 168 people
- Sponsor
- Curasight
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Prostate Cancer
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
- Trial name
- NCT06922903
- Testing
- INR101
- Where
- 32 sites in China
- Volunteers
- 240 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
High-risk Prostate Cancer
Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.
Recent evidence suggests that both standard-time and delayed-time [⁶⁸Ga]Ga-PSMA PET acquisitions can reveal clinically relevant findings, and neither phase should be excluded a priori in routine practice.
- Trial name
- SPIR202302 (NCT07357259)
- Testing
- Intervention Group
- Where
- Italy
- Volunteers
- 244 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Prostate Cancer
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
- Trial name
- NCT00588185
- Testing
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer Screening, PSMA-PET
PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy
The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing…
- Trial name
- NCT06923657
- Testing
- PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy, TRUS guided transperineal saturation biopsy
- Where
- China
- Volunteers
- 230 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostatic Neoplasms, Prostate Cancer
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
This study aims to evaluate the diagnostic performance of [68Ga]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected…
- Trial name
- NCT07830212
- Testing
- [68Ga]Ga-OncoACP3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yong He
Prostatic Neoplasms, Prostate Cancer
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT07285057
- Testing
- rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical…
- Trial name
- NCT06259123
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Prostate Cancer
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
- Trial name
- NCT07649122
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 232 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer.
- Trial name
- PRISM (NCT06523777)
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Yale University
Biochemical Recurrence of Malignant Neoplasm of Prostate
A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET
The REFINE study is evaluating whether a fluciclovine (18F) PET/CT scan can detect recurrent prostate cancer in patients whose previous PSMA PET/CT was negative or inconclusive.
- Trial name
- REFINE (NCT06859203)
- Where
- 2 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Technical University of Munich
Prostate Cancer
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer.
- Trial name
- PRIDE2-PC (NCT07568613)
- Testing
- MRI, 18F-PSMA1007 PET-CT, MR-guided TRUS Prostate biopsy
- Where
- Cyprus
- Volunteers
- 50 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Carcinoma
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
This clinical trial evaluates [18F]-rh PSMA positron emission tomography (PET)-computed tomography (CT) imaging performance in patients with prostate cancer.
- Trial name
- NCT06580015
- Testing
- Computed Tomography, Flotufolastat F-18 Gallium, Medical Device Usage and Evaluation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer (Post Prostatectomy)
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
- Trial name
- NCT06617481
- Testing
- 18F-rhPSMA-7.3 (Posluma)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth